The foundation of our transdermal business was established through strong partnerships.
Corium has demonstrated a strong track record of developing complex transdermal products for partners and manufacturing them for clinical development and commercial sale. Today, we have built on this foundation to create a balanced business model, allowing us to build a high-value proprietary CNS pipeline while continuing to create value for existing and new partners.
Corium’s two lead investigational product candidates are focused on the treatment of Alzheimer’s disease:
Proprietary Alzheimer’s Pipeline
|Corplex Donepezil||Alzheimer’s Disease||BE Completed|
|Corplex Memantine||Alzheimer’s Disease||Phase 1|
Our commercial and late-stage transdermal product opportunities include the following partnered programs:
|Crest® Whitestrips (5 Products)||Teeth Whitening|
|Twirla® (ethinyl estradiol and levonorgestrel)||Women’s Health|
The safety and efficacy of the products under investigation have not been established. There is no assurance that any of these investigational products will receive health authority approval or become commercially available in any country.